How does intravitreal bevacizumab compare with conventional laser therapy for the treatment of retinopathy of prematurity?

2018 ◽  
Author(s):  
Jane Burch ◽  
Asaf Achiron
Keyword(s):  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab ◽  
Conventional Laser

Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity

2020 ◽  
pp. 163-168
Author(s):  
Alan D. Penman ◽  
Kimberly W. Crowder ◽  
William M. Watkins
Keyword(s):  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab ◽  
Peripheral Retina ◽  
Controlled Clinical Trial ◽  
Disease Development ◽  
Retinal Vessels ◽  
Randomized Controlled Clinical Trial ◽  
Zone Ii ◽  
Conventional Laser

The Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) study was a randomized, controlled clinical trial to determine whether intravitreal bevacizumab monotherapy was an effective therapy for treating zone I or zone II posterior stage 3+ (stage 3 with plus disease) retinopathy of prematurity (ROP). Intravitreal bevacizumab, as compared with conventional laser therapy, showed a significant benefit for zone I but not zone II disease. Development of peripheral retinal vessels (with possible recurrence of ROP) continued after treatment with intravitreal bevacizumab, but conventional laser therapy led to permanent destruction of the peripheral retina.

scholarly journals Usefulness of Intravitreal Bevacizumab for Retinopathy of Prematurity with Severely Dilated Tunica Vasculosa Lentis and Poor Mydriasis

2017 ◽  
Vol 8 (1) ◽  
pp. 173-179 ◽  
Author(s):  
Tomoaki Higashiyama ◽  
Sanae Muraki ◽  
Masahito Ohji
Keyword(s):  
Birth Weight ◽  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Gold Standard ◽  
Standard Treatment ◽  
Intravitreal Bevacizumab ◽  
Male Infant ◽  
Significant Benefit ◽  
Tunica Vasculosa Lentis

Background: Laser therapy has been the gold standard treatment for retinopathy of prematurity (ROP), while intravitreal bevacizumab (IVB) is reported to be of significant benefit for zone I ROP. A problem with laser therapy is that it is difficult to administer in ROP patients with severely dilated tunica vasculosa lentis and poor mydriasis. However, although IVB treatment has been performed in such severe ROP cases, only 1 report has discussed its usefulness. Case 1: A male infant was born with a birth weight of 382 g at 23 weeks’ gestation. As visualization was poor and laser therapy could not be performed due to dilated tunica vasculosa lentis and poor mydriasis, IVB (0.625 mg/0.025 mL) was administered to both eyes. Following treatment, the ROP gradually improved, with regression of the dilated tunica vasculosa lentis and improvement of the mydriasis in both eyes. Case 2: A male infant was born with a birth weight of 698 g at 25 weeks’ gestation. As laser therapy could not be performed due to severely dilated tunica vasculosa lentis and poor mydriasis, IVB (0.625 mg/0.025 mL) was administered to both eyes. Following treatment, the ROP gradually improved, with regression of the dilated tunica vasculosa lentis and improvement of the mydriasis in both eyes. Conclusions: IVB is potentially more useful than laser therapy for the treatment of severe ROP with dilated tunica vasculosa lentis and poor mydriasis.

scholarly journals Refractive Outcomes of Patients Treated for Retinopathy of Prematurity

2021 ◽  
Vol 4 (1) ◽  
Author(s):  
Ayesha Khan ◽  
Kathryn Haider
Keyword(s):  
Laser Therapy ◽  
Refractive Error ◽  
Retinopathy Of Prematurity ◽  
High Myopia ◽  
Intravitreal Bevacizumab ◽  
Treatment Groups ◽  
Patient Demographics ◽  
Refractive Outcomes ◽  
Eye Exams ◽  
Lost To Follow Up

Background:  Retinopathy of prematurity (ROP) is a disease where the blood vessels in the eye fail to develop appropriately in infants born prematurely. Two effective treatments for ROP include laser photocoagulation therapy and intravitreal bevacizumab (IVB). Laser therapy has been linked to causing high myopia in children post-treatment. We hypothesize that patients treated with IVB alone or in combination with laser will have less myopia development than patients treated with laser therapy alone.  Methods:  Patient demographics, treatment details, refractive data at 6-9 months and 3-4 years, the occurrence of strabismus at 3 years, and the most recent vision data were collected from 133 ROP patients. Patients not treated at IU health and those lost to follow-up, or deceased before both eye exams, were excluded from the study. Quantitative analysis was used to compare the refractive error, strabismus, and vision outcomes between the three treatment groups. A linear regression model was used to analyze the relationship between the number of laser spots applied and refractive error.  Results:  Refractive outcomes at 6-9 months and 3-4 years, occurrence of strabismus, and vision outcomes were statistically similar between the three treatment groups. However, the laser group had the most occurrences of high myopia. We also observed a 0.002 unit decrease in refractive error, reported at 6–9-months, with each laser spot applied (p<0.001). This may be due to the influence of outliers because no significant relationship was seen at the 3–4 year exam.  Conclusion and Potential Impact:  There was no difference in outcomes among patients treated with IVB, laser, or a combination of both, with the exception of more myopic outliers in the laser-only group. We can therefore assume that ROP patients who have received one of these three treatments had developed differences in myopia independent of treatment modality. 

scholarly journals Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy*

2016 ◽  
Vol 46 ◽  
pp. 764-768
Author(s):  
Ahmet Murad HONDUR ◽  
Mehmet Özgür ÇUBUK ◽  
Zühal ÖZEN TUNAY ◽  
Hatice Tuba ATALAY ◽  
Özdemir ÖZDEMİR ◽  
...  
Keyword(s):  
Laser Therapy ◽  
Retinopathy Of Prematurity ◽  
Intravitreal Bevacizumab
Sign in / Sign up

Export Citation Format

Share Document